Evidence map›Paper›PMID 25906289›Full record

ArticleJournal of gastroenterology2016

NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.

Yoko Oshima, Hideaki Shimada, Satoshi Yajima, Tatsuki Nanami, Kazuyuki Matsushita, Fumio Nomura, Osamu Kainuma, Nobuhiro Takiguchi, Hiroaki Soda, Takeshi Ueda and 10 more

Erratum issuedAbstract readEvaluation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Novel combined tumor autoantibody detection in serological diagnosis of gastric cancer.International journal of clinical and experimental pathology · 2025
    Article
  12. NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Yoko OshimaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Hideaki ShimadaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
Satoshi YajimaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Tatsuki NanamiDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Kazuyuki MatsushitaMolecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Fumio NomuraMolecular Diagnosis, Graduate School of Medicine, Chiba University, Chiba, Japan.
Osamu KainumaDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Nobuhiro TakiguchiDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Hiroaki SodaDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Takeshi UedaDivision of Urology, Chiba Cancer Center, Chiba, Japan.
Toshihiko IizasaDivision of Thoracic Disease, Chiba Cancer Center, Chiba, Japan.
Naoto YamamotoDivision of Breast Surgery, Chiba Cancer Center, Chiba, Japan.
Hiroshi YamamotoDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Matsuo NagataDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Sana YokoiDivision of Clinical Genomics, Chiba Cancer Center, Chiba, Japan.
Masatoshi TagawaDivision of Pathology and Cell Therapy, Chiba Cancer Center, Chiba, Japan.
Seiko OhtsukaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Akiko KuwajimaMedical & Biological Laboratories Co., Ltd, Nagoya, Japan.
Akihiro MurakamiMedical & Biological Laboratories Co., Ltd, Nagoya, Japan.
Hironori KanekoDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Chiba Cancer Center · JPToho University · JPChiba University · JPMedical & Biological Laboratories (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough serum NY-ESO-1 antibodies (s-NY-ESO-1-Abs) have been reported in patients with esophageal carcinoma, this assay system has not been used to study a large series of patients with various other cancers. PATIENTS AND

methodsSerum samples of 1969 cancer patients [esophageal cancer (n = 172), lung cancer (n = 269), hepatocellular carcinoma (n = 91), prostate cancer (n = 358), gastric cancer (n = 313), colorectal cancer (n = 262), breast cancer (n = 365)] and 74 healthy individuals were analyzed using an originally developed enzyme-linked immunosorbent assay system for s-NY-ESO-1-Abs. The optical density cut-off value, determined as the mean plus three standard deviations for serum samples from the healthy controls, was fixed at 0.165. Conventional tumor markers were also evaluated in patients with esophageal carcinoma.

resultsThe positive rate of s-NY-ESO-1-Abs in patients with esophageal cancer (31 %) was significantly higher than that in the other groups: patients with lung cancer (13 %), patients with hepatocellular carcinoma (11 %), patients with prostate cancer (10 %), patients with gastric cancer (10 %), patients with colorectal cancer (8 %), patients with breast cancer (7 %), and healthy controls (0 %). The positive rate of s-NY-ESO-1-Abs was comparable to that of serum p53 antibodies (33 %), squamous cell carcinoma antigen (36 %), carcinoembryonic antigen (26 %), and CYFRA 21-1 (18 %) and gradually increased with the tumor stage.

conclusionsThe positive rate of s-NY-ESO-1-Abs was significantly higher in patients with esophageal cancer than in patients with the other types of cancers. On the basis of its high specificity and sensitivity, even in patients with stage I tumors, s-NY-ESO-1-Abs may be one of the first choices for esophageal cancer.

Indexed as

Antibodies, NeoplasmAntigens, NeoplasmAutoantibodiesBiomarkers, TumorBreast NeoplasmsCarcinoma, Squamous CellCase-Control StudiesDiagnosis, DifferentialDigestive System NeoplasmsEarly Detection of CancerEnzyme-Linked Immunosorbent AssayEsophageal NeoplasmsFemaleHumansMaleMembrane ProteinsAntibodies, NeoplasmAntigens, NeoplasmAutoantibodiesBiomarkers, TumorCTAG1B protein, humanMembrane ProteinsEnzyme-linked immunosorbent assayEsophageal cancerNY-ESO-1Serum autoantibodyTumor marker

Identifiers

PMID25906289
OpenAlexW2063857684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.